Tumor response and estrogen suppression in breast cancer patients treated with aromatase inhibitors

Annals of Oncology

Volumn 11, Issue 8, 2000, Pages 1017-1022

  Bajetta, E ^a   Zilembo, N ^a   Bichisao, E ^b   Martinetti, A ^a   Buzzoni, R ^a   Pozzi, P ^a   Bidoli, P ^a   Ferrari, L ^a   Celio, L ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Ital Trials in Clin Oncol (ITMO)   (Italy)

Author keywords

Aromatase inhibitors; Plasma estrogen suppression; Tumour response

Indexed keywords

ANASTROZOLE; ANDROGEN; AROMATASE INHIBITOR; ESTRADIOL; ESTRONE; EXEMESTANE; FORMESTANE; LETROZOLE; VOROZOLE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; HORMONE INHIBITION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE PROGRESSION; ENZYME INHIBITORS; ESTRADIOL; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033798012     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008388823113     Document Type: Article

References (35)

1. Aromatase inhibitors and breast cancer
2. Aromatase inhibitors in metastatic breast cancer
3. Aromatase inhibition for breast cancer treatment
4. Biological background to aromatase inhibition
5. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients
6. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
7. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in post-menopausal women with breast cancer
8. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer
9. Pharmacology of new aromatase inhibitors
10. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of an overview analysis of two phase III trials
11. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate
12. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: A phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90)
13. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients
14. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double blind trial
15. New aromatase inhibitors: More selectivity, less toxicity, unfortunately, the same activity
16. The third-generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer
17. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer
18. Vorozole (Rivizor®) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen
19. Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer
20. A multicentre, randomized, pharmacokinetic, endocrine and clinical study in breast cancer patients at first relapse: Endocrine and clinical results
21. A randomized, open, parallel-group trial to compare the endocrine effects of oral anastrozole (Arimidex®) with intramuscular formestane in postmenopausal women with advanced breast cancer
22. 4-hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer
23. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor
24. The minimal effective exemestane dose for endocrine activity in advanced breast cancer
25. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cell
26. Concentrations of estrone, estradiol and estrone sulphate, and evaluation of sulphatase and aromatase activities in pre- and postmenopausal breast cancer patients
27. Intratumoral levels of estrogens in breast cancer
28. Regulation of aromatase sulphatase in breast tumor cells
29. Clinical importance of intratumoral aromatase
30. Concentrations of estrone and 4-hydroxyandrostenedione in malignant and normal breast tissue
31. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole
32. Neoadjuvant treatment with anastrozole (Arimidex) causes profound suppression of intra-tumor estrogen levels
33. Intratumoral aromatase model: The effects of letrozole (CGS 20 267)
34. Correlation of breast tumor aromatase activity and response to aromatase inhibition with aminoglutethimide
35. The importance of local synthesis of estrogen within the breast